市場調查報告書

全球灰指甲市場:至2025年的預測

Global Onychomycosis Market Research Report Forecast to 2025

出版商 Market Research Future 商品編碼 918820
出版日期 內容資訊 英文 123 Pages
訂單完成後即時交付
價格
Back to Top
全球灰指甲市場:至2025年的預測 Global Onychomycosis Market Research Report Forecast to 2025
出版日期: 2019年11月30日內容資訊: 英文 123 Pages
簡介

全球灰指甲市場至2025年預計將以6.28%的年複合成長率成長,2025年達到79億1,250萬美元的規模。灰指甲的全球性盛行率上升,平均每人的醫療費增加,糖尿病患者人口的劇增,及週邊動脈疾病(PAD)的盛行率的增加等,為該市場的成長要素。

本報告提供全球灰指甲市場的相關調查,市場機會,成長及阻礙因素,各類型、治療類型、流通管道、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 摘要整理

  • 市場魅力分析

第2章 市場介紹

  • 定義
  • 調查範圍
  • 前提條件
  • 市場結構

第3章 調查方法

  • 調查方法
  • 資料探勘
  • 二次調查
  • 一次調查
  • 預測手法
  • 市場規模估計的調查方法
    • Bottom-Up(由下而上)方法
    • Top-Down(由上而下)方法
    • 資料三角測量
    • 檢驗

第4章 市場力學

  • 概要
  • 成長要素
    • 灰指甲的全球性增加率
    • 平均每人的醫療費的上升
    • 糖尿病患者的劇增
    • 週邊動脈疾病(PAD)的盛行率增加
  • 阻礙因素
    • 灰指甲相關認識的缺乏
    • 灰指甲治療藥相關的副作用
  • 市場機會
    • 開發中產品數量增加

第5章 市場要素分析

  • 波特的五力分析
    • 供應商談判力
    • 買主談判力
    • 新加入廠商的威脅
    • 替代品的威脅
    • 產業內的競爭
  • 價值鏈分析
    • 研究開發
    • 製造業
    • 流通
    • 行銷銷售
    • 銷售後的監視

第6章 市場分析:各類型

  • 概要
  • 遠端指甲下灰指甲
  • 表在性白色灰指甲
  • 念珠菌灰指甲
  • 近端指甲下灰指甲
  • 其他

第7章 市場分析:各治療類型

  • 概要
  • 藥物治療
  • 局部療法
  • 其他

第8章 市場分析:各流通管道

  • 概要
  • 醫院藥局
  • 零售藥局
  • 其他

第9章 各地區的灰指甲市場

  • 概要
  • 南北美洲
    • 北美
    • 南美
  • 亞太地區
    • 日本
    • 澳洲
    • 中國
    • 印度
    • 韓國
    • 其他
  • 歐洲
    • 西歐
    • 東歐
  • 中東、非洲
    • 中東
    • 非洲

第10章 競爭情形

  • 概要

第11章 企業簡介

  • Bausch Health Companies, Inc.
  • Dr. Reddy's Laboratories Ltd
  • Galderma Laboratories
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services Inc.
  • Kaken Pharmaceutical Co., Ltd
  • Merz Pharma
  • Moberg Pharma AB
  • Medimetriks Pharmaceuticals, Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Taro Pharmaceuticals Industries Ltd

第12章 附錄

  • 參照資料
  • 相關報告
目錄

Global Onychomycosis Market: Information by Type (Distal Subungual Onychomycosis (DSO), White Superficial Onychomycosis (WSO), Proximal Subungual Onychomycosis (PSO), Candida Onychomycosis and others), Treatment Type (Drug Treatment, Topical Therapy and others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and others) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2025

Market analysis

Generally, onychomycosis implies to the fungal infection of the nail. The global onychomycosis market is expected to exhibit lucrative growth during the forecast period. Some of the major factors characterizing the market growth are rising global prevalence of onychomycosis, rising per capita healthcare spending, surging diabetic patient population, and increasing prevalence of peripheral artery disease (PAD). The Global Onychomycosis Market is expected to register a CAGR of 6.28% to reach 7,912.5 million by 2025. The aging population, increased ingesting of immunosuppressive drugs, rising prevalence of diseases such as human immunodeficiency virus (HIV) and diabetes that suppress the immune- status of patients, increased experience to spas and public swimming pools, wearing tight-fitting shoes and clogs, and wearing sweaty footwears have been the factors for the rise in the incidence of mycoses. Onychomycosis represents 20% to 40% of all onycho-pathies around the earth. An article published on the ScienceDirect stated that, at present, worldwide onychomycosis prevalence ranges from 2% to 50%, and it represents roughly 30% of superficial mycotic infections and 50% of all nail disorders. Additionally, onychomycosis mainly affects adults between 30 and 60 years of age. Thus, this increasing prevalence of onychomycosis across the world is fueling the necessity for treatment drugs and therapies around the globe, thereby supporting the market growth. In January 2019, Galderma Laboratories revealed the opening of a new office in Malaysia, which would help it to accelerate the growth in the region. On the contrary, the side-effects associated with onychomycosis treatment drugs as well as lack of awareness about onychomycosis are anticipated to limit the market growth over the forecast period. Onychomycosis also called tinea unguium, is a fungal infection of the toenails or fingernails that may involve any component of the nail unit, including the matrix, bed, or plate. An article published in the Journal of Tropical Medicine stated that, presently, the prevalence of onychomycosis mainly caused by nondermatophyte molds is rising around the globe.

Market segmentation

The Global Onychomycosis Market is segmented based on distal subungual onychomycosis (DSO), white trivial onychomycosis (WSO), proximal subungual onychomycosis (PSO), candida onychomycosis, as well as others. In June 2019, Janssen Research & Development, LLC, part of the Janssen Pharmaceutical Companies of J&J Services announced a partnership with the University of California, Berkeley and the University of California, San Francisco, to enlarge data science research in healthcare Based on conduct type, the global onychomycosis market has been divided into drug treatment, topical treatment, and others. The global onychomycosis market, by distribution channel, has been segmented into hospital pharmacies, retail pharmacies, and others. The retail pharmacies segment held a share of 35.8% in 2018. In November 2018, Moberg Pharma signed an exclusive agreement with Mundipharma to commercialize Emtrix in the Middle East and African region

Regional analysis

Geographically the Global Onychomycosis Market is split in regions like North & South America, Europe, Asia-Pacific, Middle east and Africa and Rest of the world. Asia-Pacific is anticipated to be the sharpest-expanding region in the global marketplace owing to the survival of huge older general population, quickly enlarging medical expertise, growing nonrefundable revenue, convenience of drugs, and high unmet clinical needs. India apprehended a share of 12.57% in onychomycosis market in 2018. The Americas is expected to hold the greatest share of the global onychomycosis market. This owes to the authority of key market participants, modern healthcare infrastructure, increasing prevalence of onychomycosis and peripheral artery illness, rising per capita healthcare outflow, and a surge in the diabetic patient population. The onychomycosis market in the Middle East and Africa is expected to witness a modest market growth rate from 2019 to 2025. The Middle East would lead the market growth, attributing to facts such as increasing partnerships or agreements to commercialize onychomycosis goods, developing healthcare infrastructure, booming medical tourism, budding healthcare industry, and growing consciousness about onychomycosis and its treatment drugs and therapies. Europe is also expected to hold a substantial market share in the coming years. This is attributed to the rising geriatric population and escalating burden of diabetes, flourishing pharmaceutical manufacturing, and growing experience rates of onychomycosis in the UK, Germany, France, and Spain.

Major players

The proposed spectators in the Global Onychomycosis Market are Pharmaceutical companies, manufacturers, Retailers, distributors, wholesalers, Investors and trade experts, Governments, associations, industrial bodies, etc. The major companies functioning in the Global Onychomycosis Market are concentrating on firming their global ways by entering into untouched markets. The projected onlookers in the Global Onychomycosis Market are companies like Galderma Laboratories (Switzerland ), Novartis AG (Switzerland), Pfizer, Inc. (the US), Taro Pharmaceuticals Industries Ltd (Israel) Bausch Health Sciences (Canada), Moberg Pharma AB (Sweden), Dr. Reddy's Laboratories Ltd (India), Medimetriks Pharmaceuticals, Inc. (US), Merz Pharma (Germany), Kaken Pharmaceutical Co., Ltd (Japan), Johnson & Johnson Services, Inc. (US) an GlaxoSmithKline plc (UK), among others.

Table of Contents

1 Executive Summary

  • 1.1 Market Attractiveness Analysis

2 Market Introduction

  • 2.1 Definition
  • 2.2 Scope of the Study
  • 2.3 Assumptions
  • 2.4 Market Structure

3 Research Methodology

  • 3.1 Research Process
  • 3.2 Data Mining
  • 3.3 Secondary Research
  • 3.4 Primary Research
  • 3.5 Forecasting Techniques
  • 3.6 Research Methodology for Market Size Estimation
    • 3.6.1 Bottom-Up Approach
    • 3.6.2 Top-Down Approach
    • 3.6.3 Data Triangulation
    • 3.6.4 Validation

4 Market Dynamics

  • 4.1 Overview
  • 4.2 Drivers
    • 4.2.1 Worldwide Rising Prevalence of Onychomycosis
    • 4.2.2 Rising Per Capita Healthcare Expenditure
    • 4.2.3 Surging Diabetic Patient Population
    • 4.2.4 Increasing Prevalence of Peripheral Artery Disease (PAD)
  • 4.3 Restraints
    • 4.3.1 Lack of Awareness About Onychomycosis
    • 4.3.2 Side-Effects Associated with Onychomycosis Treatment Drugs
  • 4.4 Opportunity
    • 4.4.1 Increase in the Number of Pipeline Products

5 Market Factor Analysis

  • 5.1 Porter's Five Forces Model
    • 5.1.1 Bargaining Power of Suppliers
    • 5.1.2 Bargaining Power of Buyers
    • 5.1.3 Threat of New Entrants
    • 5.1.4 Threat of Substitutes
    • 5.1.5 Intensity of Rivalry
  • 5.2 Value Chain Analysis
    • 5.2.1 R&D
    • 5.2.2 Manufacturing
    • 5.2.3 Distribution
    • 5.2.4 Marketing & Sales
    • 5.2.5 Post-Sales Monitoring

6 Global Onychomycosis Market, by Type

  • 6.1 Overview
  • 6.2 Distal Subungual Onychomycosis
  • 6.3 White Superficial Onychomycosis
  • 6.4 Candida Onychomycosis
  • 6.5 Proximal Subungual Onychomycosis
  • 6.6 Others

7 Global Onychomycosis Market, by Treatment Type

  • 7.1 Overview
  • 7.2 Drug Treatment
  • 7.3 Topical Therapy
  • 7.4 Others

8 Global Onychomycosis Market, by Distribution Channel

  • 8.1 Overview
  • 8.2 Hospital Pharmacies
  • 8.3 Retail Pharmacies
  • 8.4 Others

9 Global Onychomycosis Market, by Region

  • 9.1 Overview
  • 9.2 Americas
    • 9.2.1 North America
      • 9.2.1.1 US
      • 9.2.1.2 Canada
    • 9.2.2 Latin America
  • 9.3 Asia-Pacific
    • 9.3.1 Japan
    • 9.3.2 Australia
    • 9.3.3 China
    • 9.3.4 India
    • 9.3.5 South Korea
    • 9.3.6 Rest of Asia-Pacific
  • 9.4 Europe
    • 9.4.1 Western Europe
      • 9.4.1.1 Germany
      • 9.4.1.2 France
      • 9.4.1.3 UK
      • 9.4.1.4 Italy
      • 9.4.1.5 Spain
      • 9.4.1.6 Rest of Western Europe
    • 9.4.2 Eastern Europe
  • 9.5 Middle East & Africa
    • 9.5.1 Middle East
    • 9.5.2 Africa

10 Competitive Landscape

  • 10.1 Overview

11 Company Profile

  • 11.1 Bausch Health Companies, Inc.
    • 11.1.1 Company Overview
    • 11.1.2 Financial Overview
    • 11.1.3 Products/Services Offered
    • 11.1.4 Key Developments
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Strategies
  • 11.2 Dr. Reddy's Laboratories Ltd
    • 11.2.1 Company Overview
    • 11.2.2 Financial Overview
    • 11.2.3 Products/Services Offered
    • 11.2.4 Key Developments
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Strategies
  • 11.3 Galderma Laboratories
    • 11.3.1 Company Overview
    • 11.3.2 Financial Overview
    • 11.3.3 Products/Services Offered
    • 11.3.4 Key Developments
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Strategies
  • 11.4 GlaxoSmithKline PLC
    • 11.4.1 Company Overview
    • 11.4.2 Financial Overview
    • 11.4.3 Products/Services Offered
    • 11.4.4 Key Developments
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Strategies
  • 11.5 Johnson & Johnson Services Inc.
    • 11.5.1 Company Overview
    • 11.5.2 Financial Overview
    • 11.5.3 Products/Services Offered
    • 11.5.4 Key Developments
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Strategies
  • 11.6 Kaken Pharmaceutical Co., Ltd
    • 11.6.1 Company Overview
    • 11.6.2 Financial Overview
    • 11.6.3 Products/Services Offered
    • 11.6.4 Key Developments
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Strategies
  • 11.7 Merz Pharma
    • 11.7.1 Company Overview
    • 11.7.2 Financial Overview
    • 11.7.3 Products/Services Offered
    • 11.7.4 Key Developments
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Strategies
  • 11.8 Moberg Pharma AB
    • 11.8.1 Company Overview
    • 11.8.2 Financial Overview
    • 11.8.3 Products/Services Offered
    • 11.8.4 Key Developments
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Strategies
  • 11.9 Medimetriks Pharmaceuticals, Inc.
    • 11.9.1 Company Overview
    • 11.9.2 Financial Overview
    • 11.9.3 Products/Services Offered
    • 11.9.4 Key Developments
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Strategy
  • 11.1 Novartis AG
    • 11.10.1 Company Overview
    • 11.10.2 Financial Overview
    • 11.10.3 Products/Services Offered
    • 11.10.4 Key Developments
    • 11.10.5 SWOT Analysis
    • 11.10.6 Key Strategies
  • 11.11 Pfizer, Inc.
    • 11.11.1 Company Overview
    • 11.11.2 Financial Overview
    • 11.11.3 Products/Services Offered
    • 11.11.4 Key Developments
    • 11.11.5 SWOT Analysis
    • 11.11.6 Key Strategies
  • 11.12 Taro Pharmaceuticals Industries Ltd
    • 11.12.1 Company Overview
    • 11.12.2 Financial Overview
    • 11.12.3 Products/Services Offered
    • 11.12.4 Key Developments
    • 11.12.5 SWOT Analysis
    • 11.12.6 Key Strategies

12 Appendix

  • 12.1 References
  • 12.2 Related Reports

List of Tables

  • TABLE 1 LIST OF ASSUMPTIONS
  • TABLE 2 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
  • TABLE 3 ONYCHOMYCOSIS TREATMENT DRUGS PIPELINE
  • TABLE 4 GLOBAL ONYCHOMYCOSIS MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 5 GLOBAL ONYCHOMYCOSIS MARKET FOR DISTAL SUBUNGUAL ONYCHOMYCOSIS, BY REGION 2016-2025 (USD MILLION)
  • TABLE 6 GLOBAL ONYCHOMYCOSIS MARKET FOR WHITE SUPERFICIAL ONYCHOMYCOSIS, BY REGION 2016-2025 (USD MILLION)
  • TABLE 7 GLOBAL ONYCHOMYCOSIS MARKET FOR CANDIDA ONYCHOMYCOSIS, BY REGION 2016-2025 (USD MILLION)
  • TABLE 8 GLOBAL ONYCHOMYCOSIS MARKET FOR PROXIMAL SUBUNGUAL ONYCHOMYCOSIS, BY REGION 2016-2025 (USD MILLION)
  • TABLE 9 GLOBAL ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2016-2025 (USD MILLION)
  • TABLE 10 GLOBAL ONYCHOMYCOSIS MARKET FOR DRUG TREATMENT, BY REGION 2016-2025 (USD MILLION)
  • TABLE 11 GLOBAL ONYCHOMYCOSIS MARKET FOR TOPICAL THERAPY, BY REGION 2016-2025 (USD MILLION)
  • TABLE 12 GLOBAL ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2016-2025, (USD MILLION)
  • TABLE 13 GLOBAL ONYCHOMYCOSIS MARKET FOR HOSPITAL PHARMACIES, BY REGION 2016-2025 (USD MILLION)
  • TABLE 14 GLOBAL ONYCHOMYCOSIS MARKET FOR RETAIL PHARMACIES, BY REGION 2016-2025 (USD MILLION)
  • TABLE 15 GLOBAL ONYCHOMYCOSIS MARKET, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 16 AMERICAS: ONYCHOMYCOSIS MARKET, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 17 AMERICAS: ONYCHOMYCOSIS MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 18 AMERICAS: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2016-2025 (USD MILLION)
  • TABLE 19 AMERICAS: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2016-2025 (USD MILLION)
  • TABLE 20 NORTH AMERICA: ONYCHOMYCOSIS MARKET, BY COUNTRY, 2016-2025 (USD MILLION)
  • TABLE 21 NORTH AMERICA: ONYCHOMYCOSIS MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 22 NORTH AMERICA: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2016-2025 (USD MILLION)
  • TABLE 23 NORTH AMERICA: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2016-2025 (USD MILLION)
  • TABLE 24 US: ONYCHOMYCOSIS MARKET, BY TYPE, 2016-2025, (USD MILLION)
  • TABLE 25 US: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2016-2025, (USD MILLION)
  • TABLE 26 US: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2016-2025, (USD MILLION)
  • TABLE 27 CANADA: ONYCHOMYCOSIS MARKET, BY TYPE, 2016-2025, (USD MILLION)
  • TABLE 28 CANADA: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2016-2025, (USD MILLION)
  • TABLE 29 CANADA: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2016-2025, (USD MILLION)
  • TABLE 30 LATIN AMERICA: ONYCHOMYCOSIS MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 31 LATIN AMERICA: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2016-2025 (USD MILLION)
  • TABLE 32 LATIN AMERICA: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2016-2025 (USD MILLION)
  • TABLE 33 ASIA-PACIFIC: ONYCHOMYCOSIS MARKET, BY COUNTRY, 2016-2025 (USD MILLION)
  • TABLE 34 ASIA-PACIFIC: ONYCHOMYCOSIS MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 35 ASIA-PACIFIC: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2016-2025 (USD MILLION)
  • TABLE 36 ASIA-PACIFIC: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2016-2025 (USD MILLION)
  • TABLE 37 JAPAN: ONYCHOMYCOSIS MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 38 JAPAN: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2016-2025 (USD MILLION)
  • TABLE 39 JAPAN: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2016-2025 (USD MILLION)
  • TABLE 40 AUSTRALIA: ONYCHOMYCOSIS MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 41 AUSTRALIA: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2016-2025 (USD MILLION)
  • TABLE 42 AUSTRALIA: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2016-2025 (USD MILLION)
  • TABLE 43 CHINA: ONYCHOMYCOSIS MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 44 CHINA: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2016-2025 (USD MILLION)
  • TABLE 45 CHINA: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2016-2025 (USD MILLION)
  • TABLE 46 INDIA: ONYCHOMYCOSIS MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 47 INDIA: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2016-2025 (USD MILLION)
  • TABLE 48 INDIA: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2016-2025 (USD MILLION)
  • TABLE 49 SOUTH KOREA: ONYCHOMYCOSIS MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 50 SOUTH KOREA: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2016-2025 (USD MILLION)
  • TABLE 51 SOUTH KOREA: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2016-2025 (USD MILLION)
  • TABLE 52 REST OF ASIA-PACIFIC: ONYCHOMYCOSIS MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 53 REST OF ASIA-PACIFIC: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2016-2025 (USD MILLION)
  • TABLE 54 REST OF ASIA-PACIFIC: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2016-2025 (USD MILLION)
  • TABLE 55 EUROPE: ONYCHOMYCOSIS MARKET, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 56 EUROPE: ONYCHOMYCOSIS MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 57 EUROPE: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2016-2025 (USD MILLION)
  • TABLE 58 EUROPE: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2016-2025 (USD MILLION)
  • TABLE 59 WESTERN EUROPE: ONYCHOMYCOSIS MARKET, BY COUNTRY, 2016-2025 (USD MILLION)
  • TABLE 60 WESTERN EUROPE: ONYCHOMYCOSIS MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 61 WESTERN EUROPE: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2016-2025 (USD MILLION)
  • TABLE 62 WESTERN EUROPE: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2016-2025 (USD MILLION)
  • TABLE 63 GERMANY: ONYCHOMYCOSIS MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 64 GERMANY: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2016-2025 (USD MILLION)
  • TABLE 65 GERMANY: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2016-2025 (USD MILLION)
  • TABLE 66 FRANCE: ONYCHOMYCOSIS MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 67 FRANCE: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2016-2025 (USD MILLION)
  • TABLE 68 FRANCE: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2016-2025 (USD MILLION)
  • TABLE 69 UK: ONYCHOMYCOSIS MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 70 UK: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2016-2025 (USD MILLION)
  • TABLE 71 UK: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2016-2025 (USD MILLION)
  • TABLE 72 ITALY: ONYCHOMYCOSIS MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 73 ITALY: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2016-2025 (USD MILLION)
  • TABLE 74 ITALY: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2016-2025 (USD MILLION)
  • TABLE 75 SPAIN: ONYCHOMYCOSIS MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 76 SPAIN: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2016-2025 (USD MILLION)
  • TABLE 77 SPAIN: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2016-2025 (USD MILLION)
  • TABLE 78 REST OF WESTERN EUROPE: ONYCHOMYCOSIS MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 79 REST OF WESTERN EUROPE: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2016-2025 (USD MILLION)
  • TABLE 80 REST OF WESTERN EUROPE: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2016-2025 (USD MILLION)
  • TABLE 81 EASTERN EUROPE: ONYCHOMYCOSIS MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 82 EASTERN EUROPE: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2016-2025 (USD MILLION)
  • TABLE 83 EASTERN EUROPE: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2016-2025 (USD MILLION)
  • TABLE 84 MIDDLE EAST & AFRICA: ONYCHOMYCOSIS MARKET, BY REGION, 2018 AND 2025
  • TABLE 85 MIDDLE EAST & AFRICA: ONYCHOMYCOSIS MARKET, BY REGION, 2016-2025 (USD MILLION)
  • TABLE 86 MIDDLE EAST & AFRICA: ONYCHOMYCOSIS MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 87 MIDDLE EAST & AFRICA: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2016-2025 (USD MILLION)
  • TABLE 88 MIDDLE EAST & AFRICA: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2016-2025 (USD MILLION)
  • TABLE 89 MIDDLE EAST: ONYCHOMYCOSIS MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 90 MIDDLE EAST: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2016-2025 (USD MILLION)
  • TABLE 91 MIDDLE EAST: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2016-2025 (USD MILLION)
  • TABLE 92 AFRICA: ONYCHOMYCOSIS MARKET, BY TYPE, 2016-2025 (USD MILLION)
  • TABLE 93 AFRICA: ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2016-2025 (USD MILLION)
  • TABLE 94 AFRICA: ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2016-2025 (USD MILLION)
  • TABLE 95 GLOBAL ONYCHOMYCOSIS MARKET: COMPANY SHARE ANALYSIS, 2018 (%)

List of Figures

  • FIGURE 1 MARKET SYNOPSIS
  • FIGURE 2 MARKET ATTRACTIVENESS ANALYSIS: GLOBAL ONYCHOMYCOSIS MARKET
  • FIGURE 3 GLOBAL ONYCHOMYCOSIS MARKET SHARE, BY TYPE, 2018 (%)
  • FIGURE 4 GLOBAL ONYCHOMYCOSIS MARKET, BY TYPE, 2017-2025 (USD MILLION)
  • FIGURE 5 GLOBAL ONYCHOMYCOSIS MARKET SHARE, BY TREATMENT TYPE, 2018 (%)
  • FIGURE 6 GLOBAL ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2017-2025 (USD MILLION)
  • FIGURE 7 GLOBAL ONYCHOMYCOSIS MARKET SHARE, BY DISTRIBUTION CHANNEL, 2018 (%)
  • FIGURE 8 GLOBAL ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2017-2025 (USD MILLION)
  • FIGURE 9 GLOBAL ONYCHOMYCOSIS MARKET: MARKET STRUCTURE
  • FIGURE 10 PRIMARY RESPONDENT'S BREAKDOWN
  • FIGURE 11 BOTTOM-UP AND TOP-DOWN APPROACH
  • FIGURE 12 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL ONYCHOMYCOSIS MARKET
  • FIGURE 13 PORTER'S FIVE FORCES ANALYSIS: GLOBAL ONYCHOMYCOSIS MARKET
  • FIGURE 14 VALUE CHAIN ANALYSIS OF THE GLOBAL ONYCHOMYCOSISMARKET
  • FIGURE 15 GLOBAL ONYCHOMYCOSIS MARKET SHARE, BY TYPE, 2018 (%)
  • FIGURE 16 GLOBAL ONYCHOMYCOSIS MARKET, BY TYPE, 2018 AND 2025 (USD MILLION)
  • FIGURE 17 GLOBAL ONYCHOMYCOSIS MARKET SHARE, BY TREATMENT TYPE, 2018 (%)
  • FIGURE 18 GLOBAL ONYCHOMYCOSIS MARKET, BY TREATMENT TYPE, 2018 AND 2025 (USD MILLION)
  • FIGURE 19 GLOBAL ONYCHOMYCOSIS MARKET SHARE, BY DISTRIBUTION CHANNEL, 2018 (%)
  • FIGURE 20 GLOBAL ONYCHOMYCOSIS MARKET, BY DISTRIBUTION CHANNEL, 2018 AND 2025 (USD MILLION)
  • FIGURE 21 GLOBAL ONYCHOMYCOSIS MARKET SHARE, BY REGION, 2018 (%)
  • FIGURE 22 GLOBAL ONYCHOMYCOSIS MARKET, BY REGION, 2018 AND 2025 (USD MILLION)
  • FIGURE 23 AMERICAS: ONYCHOMYCOSIS MARKET, BY REGION, 2018 AND 2025
  • FIGURE 24 NORTH AMERICA: ONYCHOMYCOSIS MARKET, BY COUNTRY, 2018 AND 2025
  • FIGURE 25 ASIA-PACIFIC: ONYCHOMYCOSIS MARKET, BY COUNTRY, 2018 AND 2025
  • FIGURE 26 EUROPE: ONYCHOMYCOSIS MARKET, BY REGION, 2018 AND 2025
  • FIGURE 27 WESTERN EUROPE: ONYCHOMYCOSIS MARKET, BY COUNTRY, 2018 AND 2025
Back to Top